Caplin Point Laboratories (524742) Q4 24/25 earnings summary

Executive summary

• Achieved consolidated revenue of ₹2,034 Cr for FY25, up 15.5% YoY, and PAT of ₹541 Cr, up 17.3% YoY, with strong cash flows and high returns on equity and capital employed.

• US market EBITDA crossed ₹102 Cr, growing 71% YoY; Caplin Steriles revenue reached ₹366 Cr, up 15% YoY, with strong growth in ophthalmics and new product approvals.

• Maintained a debt-free, cash-rich balance sheet, with free cash reserves at ₹1,180 Cr and liquid assets at ₹2,150 Cr as of March 31, 2025.

• Continued expansion in Latin America, US, and regulated markets, with new product launches, asset-light outsourcing, and backward integration as key growth drivers.

• Board declared an interim dividend of ₹3.00 per share for FY25.

Financial highlights

• Q4 FY25 revenue from operations: ₹502.5 Cr (up 10.9% YoY); FY25 revenue: ₹2,034 Cr (up 15.5% YoY); FY25 PAT: ₹541 Cr (up 17.3% YoY).

• FY25 EBITDA: ₹743.4 Cr (up 20.2% YoY); EBITDA margin at 36.5%; gross margin at 60.2%; PAT margin at 26.6%.

• Net worth increased to ₹2,850 Cr; basic EPS for FY25: ₹70.57 (up 17.2% YoY).

• Free cash flow for FY25 at ₹240 Cr; cash and cash equivalents at ₹1,180 Cr.

• Inventory of ₹335 Cr expected to yield ₹900 Cr in revenue.

Outlook and guidance

• Management expects a transition period of 18–24 months before significant growth from new initiatives materializes.

• Expects 10–12 ANDA approvals in FY26, supporting further US market growth; ongoing capex projects (~₹1,000 Cr) to expand production and product range, funded by internal accruals.

• Focus on expanding product registrations and launches in Latin America, US, and regulated markets, with asset-light outsourcing and backward integration.